-
1
-
-
38049084406
-
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
-
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem. 2007; 2:58-61.
-
(2007)
Chem Med Chem
, vol.2
, pp. 58-61
-
-
Pan, Z.1
Scheerens, H.2
Li, S.J.3
Schultz, B.E.4
Sprengeler, P.A.5
Burrill, L.C.6
Mendonca, R.V.7
Sweeney, M.D.8
Scott, K.C.9
Grothaus, P.G.10
Jeffery, D.A.11
Spoerke, J.M.12
Honigberg, L.A.13
-
2
-
-
84897055483
-
Targeting Bruton's tyrosine kinase in B cell malignancies
-
Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014; 14:219-232.
-
(2014)
Nat Rev Cancer
, vol.14
, pp. 219-232
-
-
Hendriks, R.W.1
Yuvaraj, S.2
Kil, L.P.3
-
3
-
-
84881225049
-
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
-
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369:507-516.
-
(2013)
N Engl J Med
, vol.369
, pp. 507-516
-
-
Wang, M.L.1
Rule, S.2
Martin, P.3
Goy, A.4
Auer, R.5
Kahl, B.S.6
Jurczak, W.7
Advani, R.H.8
Romaguera, J.E.9
Williams, M.E.10
Barrientos, J.C.11
Chmielowska, E.12
Radford, J.13
-
4
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369:32-42.
-
(2013)
N Engl J Med
, vol.369
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Flinn, I.W.4
Burger, J.A.5
Blum, K.A.6
Grant, B.7
Sharman, J.P.8
Coleman, M.9
Wierda, W.G.10
Jones, J.A.11
Zhao, W.12
Heerema, N.A.13
-
5
-
-
84910071839
-
Ibrutinib for the treatment of mantle cell lymphoma
-
Herrera AF, Jacobsen ED. Ibrutinib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2014; 20:5365-5371.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5365-5371
-
-
Herrera, A.F.1
Jacobsen, E.D.2
-
6
-
-
84897901864
-
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
-
Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014; 123:1207-1213.
-
(2014)
Blood
, vol.123
, pp. 1207-1213
-
-
Woyach, J.A.1
Bojnik, E.2
Ruppert, A.S.3
Stefanovski, M.R.4
Goettl, V.M.5
Smucker, K.A.6
Smith, L.L.7
Dubovsky, J.A.8
Towns, W.H.9
MacMurray, J.10
Harrington, B.K.11
Davis, M.E.12
Gobessi, S.13
-
7
-
-
84922787400
-
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT, BCL2 pathways
-
Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT, BCL2 pathways. Br J Haematol. 2015; 168:765-768.
-
(2015)
Br J Haematol
, vol.168
, pp. 765-768
-
-
Zhao, X.1
Bodo, J.2
Sun, D.3
Durkin, L.4
Lin, J.5
Smith, M.R.6
Hsi, E.D.7
-
8
-
-
84897853580
-
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
-
Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014; 123:1229-1238.
-
(2014)
Blood
, vol.123
, pp. 1229-1238
-
-
Rushworth, S.A.1
Murray, M.Y.2
Zaitseva, L.3
Bowles, K.M.4
MacEwan, D.J.5
-
9
-
-
84867589196
-
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB
-
Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal. 2013; 25:106-112.
-
(2013)
Cell Signal
, vol.25
, pp. 106-112
-
-
Rushworth, S.A.1
Bowles, K.M.2
Barrera, L.N.3
Murray, M.Y.4
Zaitseva, L.5
MacEwan, D.J.6
-
10
-
-
84929465568
-
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
-
Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, et al. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014; 106.
-
(2014)
J Natl Cancer Inst
, pp. 106
-
-
Gao, W.1
Wang, M.2
Wang, L.3
Lu, H.4
Wu, S.5
Dai, B.6
Ou, Z.7
Zhang, L.8
Heymach, J.V.9
Gold, K.A.10
Minna, J.11
Roth, J.A.12
Hofstetter, W.L.13
-
11
-
-
77955625479
-
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
-
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010; 107:13075-13080.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 13075-13080
-
-
Honigberg, L.A.1
Smith, A.M.2
Sirisawad, M.3
Verner, E.4
Loury, D.5
Chang, B.6
Li, S.7
Pan, Z.8
Thamm, D.H.9
Miller, R.A.10
Buggy, J.J.11
-
12
-
-
84906307152
-
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
-
Lanning BR, Whitby LR, Dix MM, Douhan J, Gilbert AM, Hett EC, Johnson TO, Joslyn C, Kath JC, Niessen S, Roberts LR, Schnute ME, Wang C, et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat Chem Biol. 2014; 10:760-767.
-
(2014)
Nat Chem Biol
, vol.10
, pp. 760-767
-
-
Lanning, B.R.1
Whitby, L.R.2
Dix, M.M.3
Douhan, J.4
Gilbert, A.M.5
Hett, E.C.6
Johnson, T.O.7
Joslyn, C.8
Kath, J.C.9
Niessen, S.10
Roberts, L.R.11
Schnute, M.E.12
Wang, C.13
-
13
-
-
19744364796
-
Structural bioinformatics-based design of selective, irreversible kinase inhibitors
-
Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science. 2005; 308:1318-1321.
-
(2005)
Science
, vol.308
, pp. 1318-1321
-
-
Cohen, M.S.1
Zhang, C.2
Shokat, K.M.3
Taunton, J.4
-
14
-
-
33644784776
-
An efficient rapid system for profiling the cellular activities of molecular libraries
-
Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, Jarnes L, Matzen JT, Garcia ME, Hood TL, Beigi R, Xia G, Harig RA, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA. 2006; 103:3153-3158.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 3153-3158
-
-
Melnick, J.S.1
Janes, J.2
Kim, S.3
Chang, J.Y.4
Sipes, D.G.5
Gunderson, D.6
Jarnes, L.7
Matzen, J.T.8
Garcia, M.E.9
Hood, T.L.10
Beigi, R.11
Xia, G.12
Harig, R.A.13
-
15
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008; 105:2070-2075.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
Woo, M.S.4
Greulich, H.5
Wong, K.K.6
Meyerson, M.7
Eck, M.J.8
-
16
-
-
33745002702
-
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
-
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006; 125:1137-1149.
-
(2006)
Cell
, vol.125
, pp. 1137-1149
-
-
Zhang, X.1
Gureasko, J.2
Shen, K.3
Cole, P.A.4
Kuriyan, J.5
-
17
-
-
4644289313
-
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
-
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Research. 2004; 64:6652-6659.
-
(2004)
Cancer Research
, vol.64
, pp. 6652-6659
-
-
Wood, E.R.1
Truesdale, A.T.2
McDonald, O.B.3
Yuan, D.4
Hassell, A.5
Dickerson, S.H.6
Ellis, B.7
Pennisi, C.8
Horne, E.9
Lackey, K.10
Alligood, K.J.11
Rusnak, D.W.12
Gilmer, T.M.13
-
18
-
-
84887977876
-
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
-
Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013; 3:1404-1415.
-
(2013)
Cancer Discov
, vol.3
, pp. 1404-1415
-
-
Walter, A.O.1
Sjin, R.T.2
Haringsma, H.J.3
Ohashi, K.4
Sun, J.5
Lee, K.6
Dubrovskiy, A.7
Labenski, M.8
Zhu, Z.9
Wang, Z.10
Sheets, M.11
St Martin, T.12
Karp, R.13
-
19
-
-
84904898065
-
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
-
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4:1046-1061.
-
(2014)
Cancer Discov
, vol.4
, pp. 1046-1061
-
-
Cross, D.A.1
Ashton, S.E.2
Ghiorghiu, S.3
Eberlein, C.4
Nebhan, C.A.5
Spitzler, P.J.6
Orme, J.P.7
Finlay, M.R.8
Ward, R.A.9
Mellor, M.J.10
Hughes, G.11
Rahi, A.12
Jacobs, V.N.13
-
20
-
-
84922753595
-
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
-
Yap TA, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med. 2014; 7:285-295.
-
(2014)
Pharmgenomics Pers Med
, vol.7
, pp. 285-295
-
-
Yap, T.A.1
Popat, S.2
-
21
-
-
72949092456
-
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
-
Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009; 462:1070-1074.
-
(2009)
Nature
, vol.462
, pp. 1070-1074
-
-
Zhou, W.1
Ercan, D.2
Chen, L.3
Yun, C.H.4
Li, D.5
Capelletti, M.6
Cortot, A.B.7
Chirieac, L.8
Iacob, R.E.9
Padera, R.10
Engen, J.R.11
Wong, K.K.12
Eck, M.J.13
-
22
-
-
33745933955
-
HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes
-
Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr. 2006; 62:859-866.
-
(2006)
Acta Crystallogr D Biol Crystallogr
, vol.62
, pp. 859-866
-
-
Minor, W.1
Cymborowski, M.2
Otwinowski, Z.3
Chruszcz, M.4
-
23
-
-
34447508216
-
Phaser crystallographic software
-
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007; 40:658-674.
-
(2007)
J Appl Crystallogr
, vol.40
, pp. 658-674
-
-
McCoy, A.J.1
Grosse-Kunstleve, R.W.2
Adams, P.D.3
Winn, M.D.4
Storoni, L.C.5
Read, R.J.6
-
24
-
-
3543012707
-
Crystallography & NMR system: A new software suite for macromolecular structure determination
-
Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998; 54:905-921.
-
(1998)
Acta Crystallogr D Biol Crystallogr
, vol.54
, pp. 905-921
-
-
Brunger, A.T.1
Adams, P.D.2
Clore, G.M.3
DeLano, W.L.4
Gros, P.5
Grosse-Kunstleve, R.W.6
Jiang, J.S.7
Kuszewski, J.8
Nilges, M.9
Pannu, N.S.10
Read, R.J.11
Rice, L.M.12
Simonson, T.13
-
26
-
-
76449098262
-
PHENIX: a comprehensive Python-based system for macromolecular structure solution
-
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010; 66:213-221.
-
(2010)
Acta Crystallogr D Biol Crystallogr
, vol.66
, pp. 213-221
-
-
Adams, P.D.1
Afonine, P.V.2
Bunkoczi, G.3
Chen, V.B.4
Davis, I.W.5
Echols, N.6
Headd, J.J.7
Hung, L.W.8
Kapral, G.J.9
Grosse-Kunstleve, R.W.10
McCoy, A.J.11
Moriarty, N.W.12
Oeffner, R.13
-
27
-
-
7544226311
-
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes
-
Schuttelkopf AW and van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004; 60:1355-1363.
-
(2004)
Acta Crystallogr D Biol Crystallogr
, vol.60
, pp. 1355-1363
-
-
Schuttelkopf, A.W.1
van Aalten, D.M.2
|